Press Releases

Press Releases

    Date Title View
    10/25/21
    Summary ToggleMIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Complete Response Rate Using KRYSTEXXA® (pegloticase injection) with Methotrexate
    PDF Version
    10/22/21
    Summary ToggleHorizon Therapeutics plc Named to Newsweek’s List of the Most Loved Workplaces for 2021
    PDF Version
    10/21/21
    Summary ToggleNewly Published Data Continue to Support Long-Term Efficacy of TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
    PDF Version
    10/13/21
    Summary ToggleNew Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    10/12/21
    Summary ToggleNew TEPEZZA® (teprotumumab-trbw) Data to be Presented at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
    PDF Version
    10/11/21
    Summary ToggleHorizon Therapeutics plc to Release Third-Quarter 2021 Financial Results and Host Webcast on Nov. 3, 2021
    PDF Version
    10/06/21
    Summary ToggleHorizon Therapeutics plc Named One of the 2021 Top 100 Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
    PDF Version
    10/04/21
    Summary ToggleNew Analysis Published in Multiple Sclerosis Journal Assesses Long-Term Use of UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    10/04/21
    Summary ToggleHorizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2021
    PDF Version
    09/29/21
    Summary ToggleHorizon Therapeutics plc Announces New Development Programs at Virtual R&D Day
    PDF Version
    Displaying 1 - 10 of 608 results